SHAREHOLDER ALERT

Lundin Law PC Announces Ongoing Investigation of KaloBios Pharmaceuticals, Inc. and Urges Investors with Losses in Excess of $250,000 to Contact the Firm

Lundin Law PC announces it is investigating claims against KaloBios Pharmaceuticals, Inc. (“KaloBios” or the “Company”) (OTC: KBIOQ) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by KaloBios were false and misleading and/or failed to disclose material information regarding the Company’s financial performance.

To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at [e-mail].

The investigation will focus on whether the Company failed to disclose that: (1) Defendant Shkreli was currently the subject of a federal criminal investigation; (2) KaloBios' CEO was involved in a scheme involving the illegal use of stock from Retrophin, Inc. to pay off debts associated with other unrelated business dealings; and (3) the discovery or exposure of this scheme would likely undermine KaloBios' operations and prospects.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160210006358/en/